Lowers FY23 revenue view to $1.548B-$1.560B from $1.6B-$1.62B. Consensus is for FY23 EPS $3.12 and for revenue $1.56B. The revenue range represents reported growth of (0.6%)-0.2%, with organic growth of 0.3%-1.1% and reflects the full year impact of the Boston recall and the solid performance of the underlying business.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on IART:
- Integra LifeSciences Reports Second Quarter 2023 Financial Results
- Integra Lifesciences (IART) Q2 Earnings Cheat Sheet
- Integra LifeSciences price target raised to $48 from $44 at Truist
- Integra LifeSciences upgraded to Buy from Hold at Jefferies
- Integra LifeSciences to Host Second Quarter 2023 Financial Results Conference Call on July 27, 2023
